Pieris Pharmaceuticals Inc. (PIRS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Pieris Pharmaceuticals In... (PIRS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.60

-2.51 (-15.58%)

At close: Dec 13, 2024, 9:00 PM

undefined% (undefined)

Bid	9.05
Market Cap	17.96M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-12.11
PE Ratio (ttm)	-1.12
Forward PE	n/a
Analyst	n/a

Ask	15
Volume	51,728
Avg. Volume (20D)	22,969
Open	15.04
Previous Close	16.11
Day's Range	13.26 - 15.35
52-Week Range	6.20 - 22.32
Beta	undefined

About PIRS

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 2, 2015

Employees 46

Stock Exchange NASDAQ

Ticker Symbol PIRS

Website https://www.pieris.com

Why Price Moved

5 months ago · Source

+88.6%

Pieris Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

News

1 month ago · businesswire.com

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pieris Pharmac...